Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 23, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,800,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,295.61 pence per share.
- Treasury Shares Held: 371,087,158 shares (representing 6.57% of total voting rights).
- Shares in Issue: 5,651,153,310 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,800,000 shares for Treasury. Consequently, the total number of shares in issue is now 5,651,153,310, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,651,153,310) for compliance with disclosure thresholds.
- Confirm the updated Treasury share count (371,087,158) and its percentage of voting rights (6.57%).
- Review the purchase price of 1,295.61 pence per share against market prices on August 23, 2007.